Core One Labs Inc C.COOL

Alternate Symbol(s): CLABF

Healthcare Cannabis

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.

CSE:COOL - Post by User

Core One Labs Inc

Bullboard Posts

Post by wesdevrieson Aug 04, 2017 11:51pm

118 Views

Post# 26550477

An excerpt from LDS's news release Aug 25, 2016

Seems like it takes a whole year to calibrate the machines to date; this news release is not transparency...it was put out for the PP...nothing else in my opinion!

LDS, OTCQB: LDSYF, and XETR: LD6) (“LDS” or the “Company”) is pleased to announce that this week the Company will complete the equipment design modifications necessary to increase production capabilities while, simultaneously, reducing electrical requirements.

LDS, in the evolutionary process of improving its manufacturing capabilities, is completing modifications to its current equipment. The Company believes that these design modifications will benefit the production of CannaStrips by decreasing the actual footprint of the equipment by over 20% while increasing the production speed by as much as 25%. These modifications will allow for the production of CannaStrips to be manufactured more efficiently in a much smaller area, making it suitable for production in a modular facility. Brad Eckenweiler, the Company’s CEO, enthusiastically states, “We are very pleased with the results from our team’s efforts in the continuing development of our manufacturing process. The intention was to reduce our operational size while improving our capabilities. I am proud to say we have accomplished all of these objectives and the Company will certainly benefit from these accomplishments.”